MiniMed Group vs Travere Therapeutics
MiniMed Group (MMED), health care, and Travere Therapeutics (TVTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
MiniMed Group and Travere Therapeutics are valued at about the same: $5B and $4.9B. MiniMed Group's operating margin in its latest fiscal year was -6.13% and Travere Therapeutics's -12.8%. Over the past year MiniMed Group's share price has moved +0.87% and Travere Therapeutics's +38.1%.
Key facts
- MiniMed Group market value
- $5B
- Travere Therapeutics market value
- $4.9B
- MiniMed Group revenue
- $3.1BFY to 2026-04-24
- Travere Therapeutics revenue
- $490.7MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | MiniMed Group | Travere Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2026-04-24 | 2025-12-31 |
| Size | ||
| Market cap | $5Bhigher | $4.9Blower |
| Revenue | $3.1Bhigher | $490.7Mlower |
| Earnings | -$333Mlower | -$25.5Mhigher |
| Employees | 8,000higher | 497lower |
| Total assets | $4.6Bhigher | $605.2Mlower |
| Valuation | ||
| P/E | — | — |
| P/S | 1.6lower | 10.0higher |
| P/B | 1.4lower | 217higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | -6.13%higher | -12.8%lower |
| Balance sheet | ||
| Net assets | $3.6Bhigher | $114.8Mlower |
| Total liabilities | $1Bhigher | $490.4Mlower |
| Total debt | — | — |
| Cash on hand | $298Mhigher | $93Mlower |
| Price change | ||
| Today | -4.66%lower | +2.82%higher |
| 1 year | +0.87%lower | +38.1%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
MiniMed Group only (0)
None of the tracked investors.
Travere Therapeutics only (1)
- Polen Capital team<0.1%
Percentages are each holding's share of that investor's reported portfolio. · Who owns TVTX
More on MiniMed Group
Further comparisons
MiniMed Group against its closest peers
Travere Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, MiniMed Group or Travere Therapeutics?
By market value, MiniMed Group is the larger: $5B against $4.9B for Travere Therapeutics. By revenue in its latest fiscal year, MiniMed Group is the larger: $3.1B against $490.7M for Travere Therapeutics.
Which has the higher operating margin?
MiniMed Group: -6.13%, against -12.8% for Travere Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both MiniMed Group and Travere Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 0 hold MiniMed Group and 1 holds Travere Therapeutics.
Cite this page
Funkfolio, “MiniMed Group vs Travere Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/mmed-vs-tvtx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.